Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Joerg E. A. Schubert"'
Autor:
Rudolf Schlag, Joerg Trojan, Joerg E. A. Schubert, Gabriele Margareta Siegler, Nils Homann, S. Dörfel, Mark-Oliver Zahn, H.-G. Höffkes, S.-E. Al-Batran, Oliver Waidmann, G. zur Hausen, T.O. Götze, Alexander Reichart, Claudia Pauligk, Ali Aldaoud, Wolfgang Blau, Lars Hahn, C. Schönherr, M. Reiser, Michael Koenigsmann
Publikováno v:
Web of Science
Autor:
Joerg Hasford, Wolf-Karsten Hofmann, Michael Kneba, Hermann Einsele, Gabriela M. Baerlocher, Thomas Ernst, Mathias Hänel, Christiane Falge, Jolanta Dengler, Joerg E. A. Schubert, Andreas Hochhaus, Ulrike Proetel, Susanne Schnittger, Christian Dietz, Andreas Neubauer, Cornelius F. Waller, Markus Pfirrmann, Benjamin Hanfstein, Alice Fabarius, Michael Lauseker, Philipp Erben, Karsten Spiekermann, Stefan W. Krause, Martin C. Müller, Michael Pfreundschuh, Rüdiger Hehlmann, Niklas Westhoff, Frank Stegelmann, Susanne Saussele, Lothar Kanz
Publikováno v:
Blood. 124:3138-3138
[Graphic][1] Introduction: The clonal selection of a mutant BCR-ABL positive clone can be observed in about one of two patients with imatinib-resistant chronic myeloid leukemia (CML). The early detection of BCR-ABL kinase domain mutations is crucial,
Autor:
Mathias Hänel, Jolanta Dengler, Michael Lauseker, Cornelius F. Waller, Andreas Hochhaus, Andreas Neubauer, Martin Müller, Michael Kneba, Stefan W. Krause, Joerg E. A. Schubert, Gabriela M. Baerlocher, Frank Stegelmann, Karsten Spiekermann, Joerg Hasford, Lothar Kanz, Alice Fabarius, Hermann Einsele, Susanne Saussele, Rüdiger Hehlmann, Ulrike Proetel, Susanne Schnittger, Michael Pfreundschuh, Wolf-Karsten Hofmann, Philipp Erben, Markus Pfirrmann, Benjamin Hanfstein, Hans-Jochem Kolb, Valeria Shlyakhto, Christiane Falge
Publikováno v:
Blood. 120:3761-3761
Abstract 3761 Introduction: Early assessment of molecular and cytogenetic response at 3 months of imatinib treatment has been shown to predict survival and might trigger treatment intensification in slow responders who are supposed to harbor a BCR-AB
Autor:
Hans Guenter Derigs, Katja Weisel, Joerg E. A. Schubert, Martin Kaufmann, Uta Bertsch, Hans Martin, Jochen Tischler, Stefan Schmitt, Thomas Hielscher, Henk M. Lokhorst, Kai Neben, Anna Jauch, Hartmut Goldschmidt, Christiane Heiss, Laila el Jarari, Michael Pfreundschuh, Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Mathias Haenel, Marc S. Raab, Walter Lindemann, Mohammed Wattad, Ullrich Graeven, Annemiek Broyl, Steffen Luntz, Christian Teschendorf, Martin Hoffmann, Helgi van de Velde, Anthony D. Ho, Dirk Hose, Martin Goerner, Christof Scheid, Ulrich Duehrsen, Igor Wolfgang Blau, Norma Peter, Bronno van der Holt, Hans Salwender
Publikováno v:
Blood. 118:332-332
Abstract 332 PURPOSE : In Multiple Myeloma (MM), the combination of serum beta-2-microglobulin level with serum albumin concentration has been proposed as an outcome predictor in the International Staging System (ISS). More recently, subgroups of MM
Autor:
Susanne Saussele, Michael Lauseker, Andreas Neubauer, Rüdiger Hehlmann, M Hänel, Hermann Einsele, Markus Pfirrmann, Dominik Heim, Andreas Hochhaus, Joerg E. A. Schubert, Martin C. Müller, Michael Kneba, Wolf-Karsten Hofmann, Ulrike Proetel, Susanne Schnittger, Michael Pfreundschuh, Benjamin Hanfstein, Gabriela M. Baerlocher, Jörg Hasford, Lothar Kanz, Jolanta Dengler, Christiane Falge, Philipp Erben, Hans-Jochem Kolb, Christoph Nerl, Stefan W. Krause, Frank Stegelmann, Cornelius F. Waller
Publikováno v:
Blood. 118:1681-1681
Abstract 1681 Introduction: The prognostic impact of different levels of molecular remission (BCR-ABL transcript expression according to International Scale, IS) at various time points on survival under imatinib treatment is still unclear. Whereas re
Autor:
Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C Müller, Claudia Haferlach, Gudrun Göhring, Brigitte Schlegelberger, Martine Jotterand, Andreas Reiter, Susanne Jung-Munkwitz, Ulrike Proetel, Juliana Schwaab, Wolf-Karsten Hofmann, Joerg E. A. Schubert, Hermann Einsele, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Wolfgang Hiddemann, Gabriela M. Baerlocher, Michael Lauseker, Markus Pfirrmann, Susanne Saussele, Rüdiger Hehlmann, Joerg Hasford
Publikováno v:
Blood. 118:782-782
Abstract 782 Introduction: Current evidence indicates that acquired genetic instability in chronic myeloid leukemia (CML) as a consequence of the t(9;22)(q34;q11) and the resulting BCR-ABL fusion causes the continuous acquisition of additional chromo
Autor:
Dominik Heim, Michael Kneba, Dieter K. Hossfeld, Gerhard Ehninger, Gabriela M. Baerlocher, Joerg E. A. Schubert, Lothar Kanz, Annette Schreiber, Christoph Nerl, Cornelius F. Waller, Anthony D. Ho, Florian Nolte, Martin C. Müller, Markus Pfirrmann, Michael Lauseker, Stefan W. Krause, Rüdiger Hehlmann, Benjamin Hanfstein, Andreas Hochhaus, Jörg Hasford, Karsten Spiekermann, Frank Stegelmann, Susanne Saussele, Hans Pralle, M Hänel, Christiane Falge, Hermann Einsele, Wolf-Karsten Hofmann, Ulrike Proetel, Andreas Neubauer, Michael Pfreundschuh
Publikováno v:
Blood. 118:781-781
Abstract 781FN2 Introduction: Data on second line therapy with second generation tyrosine kinase inhibitors (TKI) in CML treatment were generated mainly from phase II/III industry initiated trials (Review Hehlmann Exp Op. 2011). 24-month overall surv
Autor:
Gerhard Ehninger, Cornelius F. Waller, Anthony D. Ho, Joerg E. A. Schubert, Verena S. Hoffmann, Susanne Saussele, Frank Stegelmann, Gabriela M. Baerlocher, Michael Pfreundschuh, Dominik Heim, Martin C. Müller, Dieter K. Hossfeld, Michael Kneba, Andreas Neubauer, Jörg Hasford, Christiane Falge, Hans Pralle, Hans-Jochem Kolb, Lothar Kanz, Michael Lauseker, Andreas Hochhaus, Rüdiger Hehlmann, Karsten Spiekermann, Christoph Nerl, Ulrike Proetel, Susanne Schnittger, Stefan W. Krause, Markus Pfirrmann, Benjamin Hanfstein, M Hänel, Hermann Einsele
Publikováno v:
Blood. 118:3762-3762
Abstract 3762 Introduction: The EUTOS Score was developed and validated as a prognostic tool for the achievement of complete cytogenetic response (CCR) at 18 months for chronic phase (CP) CML patients under imatinib therapy. The score identifies high
Autor:
Hubert Schrezenmeier, Antonio M. Risitano, Carlos M. de Castro, Petra Muus, Ulrich Duehrsen, Joerg E. A. Schubert, Jeff Szer, Jaroslaw P. Maciejewski, Lucio Luzzatto, Gérard Socié, Peter Hillmen, Robert A. Brodsky
Publikováno v:
Blood. 116:4237-4237
Abstract 4237 PNH is a chronic, life-threatening, acquired disease associated with deficiency of GPI-anchored complement inhibitory proteins on blood cells. The resulting defective regulation of terminal complement activation is responsible for hemol
Autor:
Lars Hahn, R. Schnell, Alexander Reichart, Joerg Trojan, Steffen Doerfel, T.O. Götze, Joerg E. A. Schubert, Wolfgang Blau, Gabriele Margareta Siegler, Nils Homann, Claudia Pauligk, Ali Aldaoud, Michael Koenigsmann, H-G. Hoeffkes, Oliver Waidmann, Jens Uhlig, B. Schöttger, G. zur Hausen, S-E. Al-Batran, Caroline Schoenherr
Publikováno v:
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab8de5450fc869df687ee12cb75293a6
https://publons.com/wos-op/publon/27618476/
https://publons.com/wos-op/publon/27618476/